14th WRIB Virtual 2020

Access Our On-Demand Scientific Presentations!

While WRIB has now come to a close, attendees can still access presentations through their WRIB registration! Log in to watch on-demand scientific presentations from our experts, and learn how we can support your large molecule programs with premier services for biomarkers, immunogenicity, PK, and cell-based assays supporting biologics, gene & cell therapies, and vaccines. Click here to log in and access our presentations!


PD Dr. Arno Kromminga, Chief Scientific Advisor at BioAgilytix, both presented and participated in a panel discussion during WRIB. His sessions focused on using the ELISPOT platform for gene therapy bioanalysis and with the single cell western blot assay.

“ELISPOT Method Development & Validation for Gene Therapies: Building on 2019 WRIB Recommendations, Practical Case Studies, Lessons Learnt, Evolving Trends”
Panel Discussion – ELISPOT & Single Cell Western Blot Assay

Dr. Kromminga joined Mr. Jason DelCarpini and Dr. Lisa Kierstead to discuss the strategies behind using the ELISPOT platform in use with the single cell western blot assay.

Jim McNally Bioanalytical PresenterDr. Jim McNally, Chief Scientific Officer at BioAgilytix, also participated at this year’s WRIB and gave a presentation as well as joined a panel discussion focused on current guidance for immunogenicity assessments and their application in cell and gene therapy programs.

“Application of Current Immunogenicity Guidance/Guideline (FDA/EMA) to Gene/Cell Therapy: Parallels and New Thoughts”
Panel Discussion – Gene Therapy Immunogenicity

Dr. McNally joined Dr. John Kamerud and Dr. Swati Gupta to discuss the evolution of immunogenicity assessments and considerations in gene therapies.


BioAgilytix headshots

Q&A with Dr. Jim McNally & Dr. Mike Nicholson

BioAgilytix’s Dr. Jim McNally, Chief Scientific Officer, & Dr. Mike Nicholson, Vice President, Operations, held an interactive roundtable discussion where they answered diverse gene therapy questions posed by the attending audience in an open Q&A.

You can still catch the Roundtable dis